Physician profile
Jeffrey Hamblin
NPI 1306823851
$1,472.61
in general payments reported to CMS, 2019-2025
15 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $64.28 · 2024: $556 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.61 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $244.13 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $243.77 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $169.88 | 2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $167.14 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $143.81 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $115.69 | 2019-2025 | Rexulti |
| Alkermes, INC. | $63.96 | 2019 | |
| Indivior INC. | $61.67 | 2019-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $56.12 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.61 | 2019 | |
| Tris Pharma INC | $37.21 | 2024-2025 | Onyda Xr, Dyanavel Xr |
| Axsome Therapeutics, INC. | $34.06 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $33.81 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.88 | 2024 | Caplyta |
| Vertical Pharmaceuticals, LLC | $16.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hamblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.